Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Comprehensive Study to Isolate Tumor-initiating Cells From Human Epithelial Malignancies

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2013 by Stanford University.
Recruitment status was  Not yet recruiting
National Institutes of Health (NIH)
Providence Foundation
Information provided by (Responsible Party):
Stanford University Identifier:
First received: January 29, 2010
Last updated: October 10, 2013
Last verified: October 2013
We hypothesize that all human malignancies harbour a subpopulation of tumor initiating cells/cancer stem cells (CSCs) that drives tumor development and potentially recurrence or metastasis of the disease. The primary aim of this study is to develop strategies for prospective isolation/enrichment of CSCs from human tumors of different tissue origins. In addition, we will characterize the signaling pathways and/or tumor specific antigens that are specific for CSCs, in order to specifically target these CSCs as the endpoint of this study.

Bladder Cancer
Skin Cancers
Bladder (Urothelial, Transitional Cell) Cancer
Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy)

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Comprehensive Study to Isolate Tumor-initiating Cells From Human Epithelial Malignancies

Resource links provided by NLM:

Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Measurement of cancer stem cells (CSCs) [ Time Frame: The current study does not include the active involvement of patients. Our study involves the collection of tumor samples from patients after surgical procedures. ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA
Bladder cancer specimens

Estimated Enrollment: 40
Study Start Date: December 2013
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
non-melanoma skin and bladder cancer patients that are recommended for surgical removal of tumor tissues

Inclusion Criteria:N/A. We will recruit all non-melanoma skin and bladder cancer patients that are recommended for surgical removal of tumor tissues. This includes patients from all ages, gender and ethnicity background. Our sample collection criteria based on the tumor size of individual (e.g. tumor samples will only be collected if it will not affect the pathological diagnosis or treatment procedures of patients).

Exclusion Criteria:N/A

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01060319

United States, California
Stanford University School of Medicine Not yet recruiting
Stanford, California, United States, 94305
Contact: Linda Quinn    650-723-6520   
Contact: Cancer Clinical Trials Office    (650) 498-4073   
Principal Investigator: Irving L. Weissman M.D.         
Sub-Investigator: Joseph C. Liao         
Sub-Investigator: Hayes Gladstone         
Sub-Investigator: Robert Chin         
Sponsors and Collaborators
Stanford University
National Institutes of Health (NIH)
Providence Foundation
Principal Investigator: Irving L. Weissman M.D. Stanford University
  More Information

Responsible Party: Stanford University Identifier: NCT01060319     History of Changes
Other Study ID Numbers: BLDR0011  SU-11062009-4360 
Study First Received: January 29, 2010
Last Updated: October 10, 2013
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Urinary Bladder Neoplasms
Skin Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Urinary Bladder Diseases
Urologic Diseases
Skin Diseases processed this record on October 26, 2016